1 completed, 1 recruiting, 1 terminated. 2 Phase 1, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Terminated 1 |
| Phase 2 | 1 | Recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Elenestinib: new trials by email Literature Review of Elenestinib trials Research Report on Elenestinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Elenestinib in Healthy Adult Female Participants Elenestinib, Midazolam, Levonorgestrel/Ethinyl Estradiol - Healthy Participants | Phase 1 | Completed | Blueprint Medicines Corporation | 20 | 2026-02-05 | 2026-04-20 |
| Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies BLU-263, Azacitidine - Advanced Systemic Mastocytosis | Phase 1 | Terminated | Blueprint Medicines Corporation | 9 | 2023-09-25 | 2025-04-10 |
| (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis Elenestinib, Placebo - Indolent Systemic Mastocytosis, Smoldering Systemic Mastocytosis | Phase 2 / Phase 3 | Recruiting | Blueprint Medicines Corporation | 534 | 2021-11-30 | 2026-10-07 |
Mastocytosis, Systemic (2) · Leukemia, Mast-Cell (1) · Myelodysplastic-Myeloproliferative Diseases (1)
Blueprint Medicines Corporation (3)
United States (3) · Belgium (2) · France (2) · Germany (2) · Netherlands (2) · Norway (2) · Spain (2) · Argentina (1) · Australia (1) · Austria (1) · Brazil (1) · Chile (1) · Colombia (1) · Czechia (1) · Denmark (1)